Ken Griffin Biocryst Pharmaceuticals Inc Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$6.41 - $8.69 $284,604 - $385,836	44,400 Added 46.54%	139,800 $1.06 Million
Q2 2024 Aug 14, 2024	BUY	$4.13 - $6.79 $166,852 - $274,316	40,400 Added 73.45%	95,400 $589,000
Q1 2024 May 15, 2024	SELL	$4.89 - $7.65 $2.02 Million - $3.16 Million	-413,300 Reduced 88.26%	55,000 $279,000
Q4 2023 Feb 14, 2024	SELL	$4.98 - $6.77 $393,420 - $534,830	-79,000 Reduced 14.43%	468,300 $2.81 Million
Q3 2023 Nov 14, 2023	SELL	$6.71 - $7.92 $374,418 - $441,936	-55,800 Reduced 9.25%	547,300 $3.87 Million
Q2 2023 Aug 14, 2023	BUY	$6.96 - $8.81 $97,440 - $123,340	14,000 Added 2.38%	603,100 $4.25 Million
Q1 2023 May 15, 2023	SELL	$7.94 - $11.84 $635,200 - $947,200	-80,000 Reduced 11.96%	589,100 $4.91 Million
Q4 2022 Feb 14, 2023	BUY	$10.5 - $14.2 $884,100 - $1.2 Million	84,200 Added 14.4%	669,100 $7.68 Million
Q3 2022 Nov 14, 2022	BUY	$10.79 - $14.81 $2.27 Million - $3.11 Million	210,000 Added 56.01%	584,900 $7.37 Million

278

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.45B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.